Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.

@article{Hening2010RotigotineIR,
  title={Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.},
  author={Wayne A. Hening and Richard P. Allen and William G. Ondo and Arthur Scott Walters and John W. Winkelman and Philip M. Becker and Richard K Bogan and June M. Fry and David B. Kudrow and Kurt W Lesh and Andreas Fichtner and Erwin Schollmayer},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2010},
  volume={25 11},
  pages={1675-83}
}
This randomized, double-blinded, placebo-controlled trial (NCT00135993) assessed efficacy and safety of the dopamine agonist rotigotine in the treatment of idiopathic restless legs syndrome (RLS) over a 6-month maintenance period. A total of 505 eligible participants with moderate to severe RLS (IRLS sum score >or= 15) were randomly assigned to five groups to receive either placebo or rotigotine (0.5, 1, 2, or 3 mg/24 hr) delivered by once-daily transdermal patch (fixed-dose regimen). The two… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials

  • D Garcı́a-Borreguero, L Ferini-Strambi, R. Kohnen
  • Eur J Neurol
  • 2008
1 Excerpt

Long-term safety and efficacy of rotigotine in idiopathic RLS: 3-year results from a multinational, open-label trial

  • D. Garcı́a-Borreguero
  • J Sleep Res
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…